4'-Modified Pyrimidine Nucleosides as Potential Anti-hepatitis C Virus (HCV) Agents

ISSN: 1875-628X (Online)
ISSN: 1570-1808 (Print)

Volume 14, 12 Issues, 2017

Download PDF Flyer

Letters in Drug Design & Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

G. Perry
University of Texas
San Antonio, TX

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 0.974
5 - Year: 2.25

4'-Modified Pyrimidine Nucleosides as Potential Anti-hepatitis C Virus (HCV) Agents

Letters in Drug Design & Discovery, 11(7): 917-921.

Author(s): Neeraj Shakya, Satish Vedi, Chao Liang, Babita Agrawal and Rakesh Kumar.

Affiliation: Department of Laboratory Medicine and Pathology, 7-28 Heritage Medical Research Centre, University of Alberta, Edmonton, AB, Canada T6G 2S2.


Herein, we have investigated novel pyrimidine nucleosides bearing a 4’-carboxyl functionality (6-10, 13 and 15) as anti-HCV agents. In this new class of compounds, 7, 9, 10 and 15 demonstrated in vitro anti-HCV activity similar to or better than a known anti-HCV drug, ribavirin. In this work, we also, surprisingly, identified a 3’-sulfoxide analog of 3’-thiacytidine (16), obtained as a side product during the synthesis of 15, as a potent inhibitor of HCV replication at the concentration similar to that of ribavirin. No detectable in vitro cytotoxicity was observed for the investigated compounds up to the highest concentration tested.


Hepatitis C virus, Anti-HCV effect, Synthesis, Nucleosides.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 7
First Page: 917
Last Page: 921
Page Count: 5
DOI: 10.2174/1570180811666140401184856
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: urooj@benthamscience.org Copyright © 2017 Bentham Science